Serum homocysteine levels are correlated with behavioral and psychological symptoms of Alzheimer’s disease

Neuropsychiatric Disease and Treatment

Volumn 10, Issue , 2014, Pages 1887-1896

  Kim, Hyun ^a   Lee, Kang Joon ^a  

^a Inje University College of Medicine   (South Korea)

Author keywords

Alzheimer s disease; Behavioral and psychological symptoms of dementia (BPSD); Homocysteine

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE;

AGED; AGGRESSION; AGITATION; ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; APATHY; ARTICLE; CLINICAL DEMENTIA RATING; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DELUSION; DEPRESSION; DYSPHORIA; EUPHORIA; FEMALE; FOLIC ACID BLOOD LEVEL; GLOBAL DETERIORATION SCALE; HUMAN; KOREAN (PEOPLE); MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUROPSYCHIATRIC INVENTORY; SOUTH KOREA; VITAMIN BLOOD LEVEL;

EID: 84908201169     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S68980     Document Type: Article

References (56)

1. Vogel T, Dali-Youcef N, Kaltenbach G, Andres E. Homocysteine, vitamin B12, folate, and cognitive functions: a systematic and critical review of the literature. Int J Clin Pract. 2009;63(7):1061-1067.
2. Nilsson K, Gustafson L, Hultberg B. Plasma homocysteine is a sensitive marker for tissue deficiency of both cobalamines and folates in a psychogeriatric population. Dement Geriatr Cogn Disord. 1999;10(6): 476-482.
3. Facila L, Nunez JE, Bertomeu V, et al. Early determination of homocysteine levels in acute coronary syndromes, is it an independent prognostic factor? Int J Cardiol. 2005;100(2):275-279.
4. Virtanen JK, Voutilainen S, Happonen P, et al. Serum homocysteine, folate, and risk of stroke: Kuopio Ischaemic Heart Disease Risk Factor (KIHD) Study. Eur J Cardiovasc Prev Rehabil. 2005;12(4):369-375.
5. Reif A, Pfuhlmann B, Lesch KP. Homocysteinemia as well as methylenetetrahydrofolate reductase polymorphism are associated with affective psychoses. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(7):1162-1168.
6. Monji A, Yanagimoto K, Maekawa T, Sumida Y, Yamazaki K, Kojima K. Plasma folate and homocysteine levels may be related to interictal “schizophrenia-like” psychosis in patients with epilepsy. J Clin Psychopharmacol. 2005;25(1):3-5.
7. Stuerenberg HJ, Mueller-Thomsen T, Methner A. Vitamin B12 plasma concentrations in Alzheimer disease. Neuro Endocrinol Lett. 2004; 25(3):176-177.
8. Engelborghs S, Vloeberghs E, Maertens K, et al. Correlations between cognitive, behavioural, and psychological findings and levels of vitamin B12 and folate in patients with dementia. Int J Geriatr Psychiatry. 2004; 19(4):365-370.
9. Meins W, Muller-Thomsen T, Meier-Baumgartner HP. Subnormal serum vitamin B12 and behavioural and psychological symptoms in Alzheimer’s disease. Int J Geriatr Psychiatry. 2000;15(5):415-418.
10. Whyte EM, Mulsant BH, Butters MA, et al. Cognitive and behavioral correlates of low vitamin B12 levels in elderly patients with progressive dementia. Am J Geriatr Psychiatry. 2002;10(3):321-327.
11. Lee DY, Lee KU, Lee JH, et al. A normative study of the Mini-Mental State Examination in the Korean elderly. Journal of Korean Neuropsychiatric Association. 2002;41(3):508-525.
12. Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139(9):1136-1139.
13. Choi SH, Na DL, Lee BH, et al. Estimating the validity of the Korean version of expanded Clinical Dementia Rating (CDR) Scale. Journal of the Korean Neurological Association. 2001;19(6):585-591.
14. Folstein MF, Robins LN, Helzer JE. The Mini-Mental State Examination. Arch Gen Psychiatry. 1983;40(7):812.
15. Park J, Kwon Y. Standardization of Korean version of the Mini-Mental State Examination (MMSE-K) for use in the elderly. Journal of Korean Neuropsychiatric Association. 1989;28:612-617.
16. Choi SH, Na DL, Lee BH, et al. The validity of the Korean version of Global Deterioration Scale. Journal of the Korean Neurological Association. 2002;20(6):612-617.
17. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12): 2308-2314.
18. Hirono N, Mori E, Ikejiri Y, et al. [Japanese version of the Neuropsychiatric Inventory - a scoring system for neuropsychiatric disturbance in dementia patients]. No To Shinkei. 1997;49(3):266-271. Japanese.
19. Fuh JL, Liu CK, Mega MS, Wang SJ, Cummings JL. Behavioral disorders and caregivers’ reaction in Taiwanese patients with Alzheimer’s disease. Int Psychogeriatr. 2001;13(1):121-128.
20. Tabet N, Rafi H, Weaving G, Lyons B, Iversen SA. Behavioural and psychological symptoms of Alzheimer type dementia are not correlated with plasma homocysteine concentration. Dement Geriatr Cogn Disord. 2006;22(5-6):432-438.
21. Chen CS, Tsai JC, Tsang HY, et al. Homocysteine levels, MTHFR C677T genotype, and MRI hyperintensities in late-onset major depressive disorder. Am J Geriatr Psychiatry. 2005;13(10):869-875.
22. Atmaca M, Tezcan E, Kuloglu M, Kirtas O, Ustundag B. Serum folate and homocysteine levels in patients with obsessive-compulsive disorder. Psychiatry Clin Neurosci. 2005;59(5):616-620.
23. Regland B, Abrahamsson L, Blennow K, Grenfeldt B, Gottfries CG. CSF-methionine is elevated in psychotic patients. J Neural Transm. 2004;111(5):631-640.
24. Piazza F, Galimberti G, Conti E, et al. Increased tissue factor pathway inhibitor and homocysteine in Alzheimer’s disease. Neurobiol Aging. 2012;33(2):226-233.
25. Raposo B, Rodriguez C, Martinez-Gonzales J, Badimon L. High levels of homocysteine inhibit lysyl oxidase (LOX) and downregulate LOX expression in vascular endothelial cells. Atherosclerosis. 2004;177(1):1-8.
26. Zhang X, Li H, Jin H, Ebin Z, Brodsky S, Goligorsky MS. Effects of homocysteine on endothelial nitric oxide production. Am J Physiol Renal Physiol. 2000;279(4):F671-F678.
27. Stuhlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation. 2001;104(21):2569-2575.
28. Fuso A, Nicolia V, Cavallaro RA, et al. B-vitamin deprivation induces hyperhomocysteinemia and brain S-adenosylhomocysteine, depletes brain S-adenosylmethionine, and enhances PS1 and BACE expression and amyloid-beta deposition in mice. Mol Cell Neurosci. 2008;37(4):731-746.
29. Pacheco-Quinto J, Rodriguez de Turco EB, DeRosa S, et al. Hyperhomocysteinemic Alzheimer’s mouse model of amyloidosis shows increased brain amyloid beta peptide levels. Neurobiol Dis. 2006;22(3):651-656.
30. Sontag E, Nunbhakdi-Craig V, Sontag JM, et al. Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation. J Neurosci. 2007;27(11):2751-2759.
31. Zhuo JM, Wang H, Pratico D. Is hyperhomocysteinemia an Alzheimer’s disease (AD) risk factor, an AD marker, or neither? Trends Pharmacol Sci. 2011;32(9):562-571.
32. Schafer JH, Glass TA, Bolla KI, Mintz M, Jedlicka AE, Schwartz BS. Homocysteine and cognitive function in a population-based study of older adults. J Am Geriatr Soc. 2005;53(3):381-388.
33. Budge MM, de Jager C, Hogervorst E, Smith AD. Total plasma homocysteine, age, systolic blood pressure, and cognitive performance in older people. J Am Geriatr Soc. 2002;50(12):2014-2018.
34. Prins ND, Den Heijer T, Hofman A, et al. Homocysteine and cognitive function in the elderly: the Rotterdam Scan Study. Neurology. 2002; 59(9):1375-1380.
35. Irizarry MC, Gurol ME, Raju S, et al. Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease. Neurology. 2005;65(9):1402-1408.
36. Chen CS, Chou MC, Yeh YC, et al. Plasma homocysteine levels and major depressive disorders in Alzheimer disease. Am J Geriatr Psychiatry. 2010;18(11):1045-1048.
37. Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry. 2000;69(2):228-232.
38. Naismith S, Hickie I, Ward PB, et al. Caudate nucleus volumes and genetic determinants of homocysteine metabolism in the prediction of psychomotor speed in older persons with depression. Am J Psychiatry. 2002;159(12):2096-2098.
39. Tiemeier H, van Tuijl HR, Hofman A, Meijer J, Kiliaan AJ, Breteler MM. Vitamin B12, folate, and homocysteine in depression: the Rotterdam Study. Am J Psychiatry. 2002;159(12):2099-2101.
40. Nabi H, Bochud M, Glaus J, et al. Association of serum homocysteine with major depressive disorder: results from a large population-based study. Psychoneuroendocrinology. 2013;38(10):2309-2318.
41. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M. “Vascular depression” hypothesis. Arch Gen Psychiatry. 1997;54(10):915-922.
42. Karabag T, Kaya A, Temizhan A, Koc F, Yavuz S, Cam S. The influence of homocysteine levels on endothelial function and their relation with microvascular complications in T2DM patients without macrovascular disease. Acta Diabetol. 2007;44(2):69-75.
43. Blasko I, Grubeck-Loebenstein B. Role of the immune system in the pathogenesis, prevention, and treatment of Alzheimer’s disease. Drugs Aging. 2003;20(2):101-113.
44. Ozbek Z, Kucukali CI, Ozkok E, et al. Effect of the methylenetetrahydrofolate reductase gene polymorphisms on homocysteine, folate, and vitamin B12 in patients with bipolar disorder and relatives. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(5):1331-1337.
45. Dittmann S, Seemuller F, Grunze HC, et al. The impact of homocysteine levels on cognition in euthymic bipolar patients: a cross-sectional study. J Clin Psychiatry. 2008;69(6):899-906.
46. Dittmann S, Seemuller F, Schwarz MJ, et al. Association of cognitive deficits with elevated homocysteine levels in euthymic bipolar patients and its impact on psychosocial functioning: preliminary results. Bipolar Disord. 2007;9(1-2):63-70.
47. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med. 2002; 346(7):476-483.
48. Seshadri S, Wolf PA, Beiser AS, et al. Association of plasma total homocysteine levels with clinical brain injury: cerebral volumes, white matter hyperintensity, and silent brain infarcts at volumetric magnetic resonance imaging in the Framingham Offspring Study. Arch Neurol. 2008;65(5):642-649.
49. Lanctot KL, Herrmann N, Black SE, et al. Apathy associated with Alzheimer’s disease: use of dextroamphetamine challenge. Am J Geriatr Psychiatry. 2008;16(7):551-557.
50. Spiro HR, Schimke RN, Welch JP. Schizophrenia in a patient with a defect in methionine metabolism. J Nerv Ment Dis. 1965;141(3):285-290.
51. Pollin W, Cardon PV Jr, Kety SS. Effects of amino acid feedings in schizophrenic patients treated with iproniazid. Science. 1961; 133(3446):104-105.
52. Regland B, Johansson BV, Grenfeldt B, Hjelmgren LT, Medhus M. Homocysteinemia is a common feature of schizophrenia. J Neural Transm Gen Sect. 1995;100(2):165-169.
53. Levine J, Stahl Z, Sela BA, Gavendo S, Ruderman V, Belmaker RH. Elevated homocysteine levels in young male patients with schizophrenia. Am J Psychiatry. 2002;159(10):1790-1792.
54. Virgos C, Martorell L, Simo JM, et al. Plasma homocysteine and the methylenetetrahydrofolate reductase C677T gene variant: lack of association with schizophrenia. Neuroreport. 1999;10(10):2035-2038.
55. Kim WK, Pae YS. Involvement of N-methyl-D-aspartate receptor and free radical in homocysteine-mediated toxicity on rat cerebellar granule cells in culture. Neurosci Lett. 1996;216(2):117-120.
56. Lipton SA, Kim WK, Choi YB, et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A. 1997;94(11):5923-5928.